| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
With more than 30 years of experience marketing to healthcare professionals, patients, and consumers, FCB Health produces work that is both strategically relevant and creatively compelling. We provide clients with multichannel capabilities, including payer strategy and marketing, professional education, video production, strategic planning, and media services.
The Villas is a luxury senior living community in New Jersey that offers upscale assisted living and personalized care. They provide a resort-like experience with luxury apartments and a wide range of amenities.
Beacon Clinical Research is a Brockton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
http://www.pinterest.com/infinitetherap/boards/